Jennifer Lynne Fox - Mar 1, 2022 Form 3 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
EVP, Ext Aff, GC, Corp Sec
Signature
/s/ S. Scott Lieberman Attorney-In-Fact
Stock symbol
EBS
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
3
Date filed
3/3/2022, 05:26 PM
Next filing
Nov 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EBS Common Stock 7.25K Mar 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EBS Employee Stock Options (Right to Buy) Mar 1, 2022 Common Stock 1.56K $64.24 Direct F2
holding EBS Employee Stock Options (Right to Buy) Mar 1, 2022 Common Stock 4.48K $61.44 Direct F2
holding EBS Employee Stock Options (Right to Buy) Mar 1, 2022 Common Stock 4.01K $93.49 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 934 shares and 6,316 unvested RSUs granted from the Emergent Stock Incentive Plan. Each RSU represents a right to receive one share of common stock. The RSUs vest in three equal installments annually on the day prior to the anniversary date of the grant.
F2 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.